Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients

Hematology Journal

Volumn 5, Issue 3, 2004, Pages 216-221

  Spencer, Andrew ^a   Seldon, Michael ^b   Deveridge, Sandra ^b   Cobcroft, Ralph ^c   Cull, Gavin ^d   Marlton, Paula ^c   Enno, Arno ^b   Gill, Devinder ^c  

^a ALFRED HOSPITAL   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Autologous transplantation; CID; Idarubicin; Myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IDARUBICIN; MELPHALAN; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; OUTPATIENT CARE; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 3142690594     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200342     Document Type: Article

References (24)

1. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clini Oncol 2002; 20: 1295-1303.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
3. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7-11.
5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493.
6. McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100: 317-325.
7. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
8. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-597.
9. Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
10. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
11. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.
12. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882-885.
13. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326-330.
14. Chisesi T, Capnist G, de Dominicis E, Dini E. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oneol 1988; 24: 681-684.
15. Ballester OF, Moscinski LC, Fields KK, Hiemenz JW, Zorsky PE, Goldstein SC et al. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Br J Haematol 1997; 96: 746-748.
16. Clark AD, Douglas KW, Mitchell LD, McQuaker IG, Parker AN, Tansey PJ et al. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br J Haematol 2002; 117: 605-612.
17. Cook G, Sharp RA, Tansey P, Franklin IM. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 1996; 93: 931-934.
18. Parameswaran R, Giles C, Boots M, Littlewood TJ, Mills MJ, Kelsey SM et al. CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br J Haematol 2000; 109: 571-575.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
21. Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B et al. Intensive treatment of multiple myeloma and criteria for complete remission. The Lancet 1989; II: 879-881.
22. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
23. Morgan GJ, Davies FE, Hawkins K, Brown J, Bell SE, Drayson MT et al. The MRC VII trial of standard versus intensive treatment in patients <65 years of age with multiple myeloma. Blood 2002; 100: 668a.
24. 2m melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. [comment]. Blood 2002; 99: 731-735.